This guideline looks at a new drug, Mirabegron. It can be used for frequency, urgency and incontinence in OAB, if antimuscarinics are not suitable, or are not effective. They do advise that it's use should be seen as part of a treatment pathway, including bladder retraining.
It is a beta-3 adrenoreceptor agonist, which activates the receptors to allow the bladder to relax, allowing it to store more urine.
Latest posts by Louise Hudman (see all)
- Nice | Who should we be testing for cirrhosis? - October 3, 2016
- Nice | Non-alcoholic fatty liver disease NAFLD - August 26, 2016
- Evolocumab and Alirocumab for treating dyslipidaemia - August 25, 2016